Current status of haploidentical stem cell transplantation
- 16 October 2006
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 135 (4) , 423-437
Abstract
Summary: Haploidentical stem cell transplantation is an alternative transplant strategy for patients without an human leucocyte antigen‐matched donor. The historical experience with haploidentical stem cell transplantation has been characterised by the immunological consequences of crossing a major histocompatibility barrier, namely graft‐versus‐host disease (GVHD), graft rejection and impaired immune reconstitution. Ex vivo T‐cell depletion of the graft may reduce the risk of GVHD, but at the expense of a higher risk of engraftment failure and relapse of the underlying malignancy. Myeloablative transplant strategies using vigorously T‐cell‐depleted ‘megadose’ stem cells appear to have improved the outcomes of selected patients with acute leukaemia. Non‐myeloablative stem cell transplantation strategies, in which mixed chimaerism as a platform for adoptive cellular immunotherapy is intentionally induced, show promise for limiting GVHD and lessening transplant‐related mortality. Future approaches, based on promising preclinical and early clinical observations, may include selective allodepletion of the graft, and manipulation of the cellular environment post‐transplant using selected cellular populations or immunomodulatory soluble factors.Keywords
This publication has 131 references indexed in Scilit:
- Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantationBlood, 2006
- Monoclonal antibodies as therapeutic agents for cancerThe Lancet Oncology, 2004
- Interleukin-12 and the regulation of innate resistance and adaptive immunityNature Reviews Immunology, 2003
- Prevention of Graft Versus Host Disease by Inactivation of Host Antigen-Presenting CellsScience, 1999
- Bone Marrow NK1.1− and NK1.1+ T Cells Reciprocally Regulate Acute Graft versus Host DiseaseJournal of Experimental Medicine, 1999
- Implications for immunosurveillance of altered HLA class I phenotypes in human tumoursImmunology Today, 1997
- Allorecognition by NK cells: nonself or no self?Immunology Today, 1992
- In search of the ‘missing self’: MHC molecules and NK cell recognitionImmunology Today, 1990
- Effect of HLA Compatibility on Engraftment of Bone Marrow Transplants in Patients with Leukemia or LymphomaNew England Journal of Medicine, 1989
- Marrow Transplantation from Related Donors Other Than HLA-Identical SiblingsNew England Journal of Medicine, 1985